We performed a genome-wide association study of non-Hispanic, white individuals with fibrotic idiopathic interstitial pneumonias (IIPs; n = 1,616) and controls (n = 4,683), with follow-up replication analyses in 876 cases and 1,890 controls. We confirmed association with TERT at 5p15, MUC5B at 11p15 and the 3q26 region near TERC, and we identified seven newly associated loci (P meta = 2.4 × 10 −8 to 1.1 × 10 −19 ), including FAM13A (4q22), DSP (6p24), OBFC1 (10q24), ATP11A (13q34), DPP9 (19p13) and chromosomal regions 7q22 and 15q14-15. Our results suggest that genes involved in host defense, cell-cell adhesion and DNA repair contribute to risk of fibrotic IIPs. With the goal of identifying additional genetic risk factors that collectively further the understanding of IIPs, we have completed a case-control genome-wide association study (GWAS; 1,616 cases and 4,683 controls) and replication study (876 cases and 1,890 controls) of IIP. We included all types of fibrotic IIP in our case group because (i) distinguishing between the IIP diagnoses is often problematic owing to substantial clinical, pathological and radiological overlap and (ii) there is strong evidence of shared genetic susceptibility, as over 40% of families with FIP have more than one type of IIP among the affected family members 13 . We also included both familial and sporadic IIPs because the MUC5B, TERT, TERC and SFTPC variants in individuals with sporadic disease provide suggestive evidence that sporadic IIPs are genetically similar to the familial form of this disease. We hypothesized that susceptibility to IIP is influenced by multiple genetic variants, acting independently or in combination, and that the same genetic variants confer risk of developing different histological types of IIP.
IIPs represent a group of lung diseases commonly characterized by pulmonary fibrosis or progressive scarring of the alveolar interstitium that can lead to significant morbidity and mortality due to hypoxemic respiratory insufficiency 1 . Although some forms of pulmonary fibrosis are associated with known environmental exposures (for example, asbestos), drug toxicity 2 , radiation exposure or collagen vascular diseases (for example, scleroderma), IIPs have no known etiology. The most common and severe IIP is idiopathic pulmonary fibrosis (IPF) 1 , which has a median survival time of 2-3 years after diagnosis. There are no IPF pharmacological therapies approved for use in the United States, and lung transplantation is the only intervention known to prolong life 3 . Although all IIPs have a variable clinical course, they often progress to end-stage lung disease and death. It seems likely that risk of IIP is determined by multiple genetic variants and environmental toxins, but the specific causes of IIP are only beginning to emerge.
The evidence for a genetic component to the risk of IIP is substantial and includes familial clustering of disease, the occurrence of pulmonary fibrosis as part of systemic genetic syndromes, considerable variability in the risk of pulmonary fibrosis among those with similar exposures to known environmental agents, such as asbestos, and the identification of genetic risk loci for IIP. Rare mutations in the TERT, TERC, SFTPC and SFTPA2 genes have been associated with familial interstitial pneumonia (FIP; defined as two or more family members with IIP) and IPF [4] [5] [6] [7] [8] [9] , and a common polymorphism in TERT has been associated with IPF 10 . Recently, we identified a promoter variant in the MUC5B gene (rs35705950) that is present in approximately 50-60% of individuals with FIP or IPF and is estimated to increase risk by 6-fold for heterozygotes and by 20-fold for homozygotes 11 . The identification of MUC5B as a common risk factor has altered our view of the pathogenesis of pulmonary fibrosis from focusing primarily on alveolar epithelia and the lung matrix to inclusion of Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
RESULTS

Genome-wide discovery
We genotyped 1,914 self-reported non-Hispanic, white individuals with fibrotic IIP (cases) on the Illumina Human 660W Quad BeadChip. Of these, 298 were excluded on the basis of being a genetic outlier (n = 14), being a first-degree relative of another case (n = 126), high heterozygosity (n = 8) or missing >2% of genotypes across all SNPs (n = 150; Online Methods), such that 1,616 cases were included in the analyses (Supplementary Tables 1-3 ). Of 15,352 out-of-study controls without phenotypic information also genotyped on the Illumina Human 660W Quad BeadChip in the same laboratory, we selected 4,683 controls who were most genetically similar to our cases on the basis of genome-wide identity-by-state (IBS) comparisons and met the same quality control criteria as cases (Online Methods and Supplementary Table 1) .
We compared cases and controls at 439,828 SNPs with (i) minor allele frequency (MAF) of >0.05; (ii) Hardy-Weinberg equilibrium (HWE) P value of >0.0001 in cases and controls evaluated separately; and (iii) P value for differential missingness between cases and controls of >0.001 if less than 2% missing and of >0.05 if between 2% and 5% missing. Neither the quantile-quantile plot of P values (Supplementary Fig. 1 ) nor the estimated genomic inflation factor (λ) of 0.99 suggested any systematic biases, such as those related to population stratification. Under an additive model for the minor allele at each SNP, we identified 19 SNPs, representing 7 chromosomal locations, with genome-wide significant (P < 5 × 10 −8 ) associations (Fig. 1 
Replication and meta-analysis
We selected the 20 genome-wide significant SNPs and an additional 178 SNPs with 5 × 10 −8 < P < 0.0001 (143 under an additive model shown between red and blue lines in Fig. 1 ; see Supplementary Tables 5 and 6 for SNP location, genotype and HWE information and Supplementary of the SNPs. Six of the 8 genome-wide significant loci (13 of 20 SNPs) were associated with IIP in the replication cohort at P < 0.0025, corresponding to conservative Bonferroni correction for 20 tests ( Table 4 ) that were genome-wide significant under an additive model in the metaanalysis but not in the GWAS discovery.
The most highly associated SNP in the GWAS discovery, rs868903 (P GWAS = 1.3 × 10 −22 ; P meta = 9.2 × 10 −26 ), is in the promoter of the MUC5B gene on chromosome 11p15, which we have previously reported to be associated with IPF and FIP 11 and which has been confirmed in other studies 14, 15 . Ten additional SNPs in the MUC5B region, including SNPs in the MUC2 and TOLLIP genes, were also genome-wide significant in the joint analysis and not in strong linkage disequilibrium (LD) with rs868903 (Fig. 2d) . The SNPs rs2736100 (P meta = 1.7 × 10 −19 ) and rs2853676 (P meta = 3.3 × 10 −8 ) on chromosome 5p15 are in the TERT gene (Fig. 2a) , and rs1881984 (P meta = 4.5 × 10 −8 ) is near the TERC gene (Fig. 3a) ; rare mutations in TERT and TERC have been reported to be associated with FIP and IPF 4, 5 , and association of rs2736100 in the TERT gene has previously been reported 10 .
The remaining eight genome-wide significant loci are newly discovered risk loci for IIP. Five of the association signals, at 4q22, 6p24, 10q24, 13q34 and 19p13, seem localized to single genes (Figs. 2  and 3 ). SNP rs2609255 (P meta = 2.2 × 10 −11 ) is in the FAM13A gene (family with sequence similarity 13, member A) at 4q22 (Fig. 3b) . SNPs rs10484326 (P meta = 5.5 × 10 −9 ) and rs2076295 (P meta = 1.1 × 10 −19 ) are in the DSP gene (desmoplakin) at 6p24 (Fig. 2b) . SNPs rs10748858 (P meta = 2.7 × 10 −8 ), rs2067832 (P meta = 3.7 × 10 −8 ) and rs11191865 (P meta = 2.4 × 10 −8 ) are in the OBFC1 gene (oligonucleotide-binding fold containing 1) at 10q24 (Fig. 3c) . SNP rs1278769 (P meta = 6.7 × 10 −9 ) is in the ATP11A gene (ATPase, class VI, type 11A) at 13q34 (Fig. 3d) . SNPs rs12610495 (P meta = 1.7 × 10 −12 ) and rs2109069 (P meta = 2.4 × 10 −11 ) are in the DPP9 gene (dipeptidylpeptidase 9) at 19p13 (Fig. 2g) . The other three chromosomal regions (7q22, 15q14-15 and 17q21) have either no significant SNP in any gene or SNPs with significant associations in multiple genes (Fig. 2c,e,f and Tables 1 and 2) . The estimated odds ratios (ORs) for all of the genome-wide significant SNPs range from ~1.1 to ~1.6 (Tables 1 and 2 ; ORs for SNPs with MAFs that are less than 1 correspond to ORs for the major alleles in this same range).
Investigation of local ancestry on chromosome 17q21
Several SNPs at the 17q21 locus were found to be significantly associated with IIP. However, the 17q21 region contains a common inversion polymorphism 16, 17 , and the haplotypes (collectively referred to as H2) that contain the inversion show marked frequency differences across European populations 16, 17 . We stratified our GWAS discovery samples by carriage of the H2 haplotypes and tested for association across the genome in those without the H2 haplotypes to assess the potential for confounding by local ancestry in the chromosome 17q21 region. We similarly stratified our replication sample for association testing at each of the replication SNPs. The association signal at chromosome 17q21 was completely confounded by carriage of an H2 haplotype in both the discovery and replication cohorts. Among those with no H2 haplotype, most of the 17q21 SNPs had too little variation to allow robust tests of association; all P values for SNPs that could be tested across the region increased substantially and none were significant (all nominal P > 0.01; Supplementary Tables 8 and 9).
After stratification by carriage of H2 haplotypes, the other genome-wide significant associations were either essentially unchanged or showed lower statistical significance, consistent with the smaller sample size in the non-H2 group (Supplementary Table 8 ). Notably, in both the discovery and replication cohorts, the ORs for each of the other loci were nearly identical in the full and stratified analyses, providing further evidence that the ancestry differences on chromosome 17q21 were not driving any of the other associations we identified. a Based on joint analysis of a subset of GWAS and all replication cases compared to replication controls to allow for adjustment for rs35705950, which was not on the GWAS panel; a subset of GWAS cases were regenotyped for the SNPs listed in supplementary table 4 and rs35705950 using the same platform and at the same time as replication cases and controls. All SNP associations were adjusted for sex. b Each SNP was tested for association in a logistic regression model that also included rs35705950 in addition to sex. c P values for rs35705950 were all <1.81 × 10 −80 after adjustment for each SNP and sex in individual logistic regression models.
Imputation across genome-wide significant loci
We imputed genotypes for HapMap 3 SNPs using IMPUTE 18 across the significantly associated regions to better understand the range over which the association signals extended and to identify additional SNPs potentially associated with IIP ( Supplementary Figs. 2 and 3 and Supplementary Table 10 ). In general, the imputation results were entirely consistent with those from genotyped SNPs. However, the imputation results implicated the TERC gene more strongly than the results from direct genotyping (Supplementary Fig. 3a ) and seemed to better localize the association signal at 7q22 to the ZKSCAN1 gene (Supplementary Fig. 2c ).
Investigation of adjusted models for genome-wide significant SNPs
To adjust for the previously discovered MUC5B promoter SNP (rs35705950; not on the Illumina Human 660W Quad BeadChip), we genotyped a subset of the GWAS discovery cases on the same platform and at the same time as the replication cases for the replication SNPs (those listed in Supplementary Table 4) . We combined the raw genotypes from these cases (n = 859) with those from the replication cases and controls for joint analyses. To assess the evidence for multiple independent association signals in each region, we tested for association with each SNP in a given region after adjusting for the most significant SNP in that region on the basis of the meta-analysis results. For the 11p15 region, we adjusted for rs35705950, given our previous findings and the strength of the association we observed between rs35705950 and IIP in our current study population (OR = 4.51, 95% confidence interval (CI) = 3.91-5.21; P joint = 7.21 × 10 −95 ). After adjustment for rs35705950, only one of the SNPs at 11p15 (rs4077759) remained nominally associated with IIP (P = 0.03; Table 3 ), whereas rs35705950 remained highly significant in all models (all P < 1.81 × 10 −80 ), suggesting that the associations we observed with other SNPs were due to weak LD with rs35705950 ( Table 3 ; see Supplementary Fig. 4 for LD among all the SNPs). The reductions in significance of SNPs in the other regions after adjustment for the top SNP were consistent with LD among the SNPs (Supplementary Table 11 ) and did not provide evidence for multiple association signals. Notably, SNP rs1881984 near the TERC gene was no longer significant after adjustment for rs6793295 in the LRRC34 gene.
Given the increased risk of IIP in males compared to females, we tested for an interaction between each of the GWAS-significant SNPs and sex. We found no strong evidence for differential effects of the SNPs based on sex after correction for the 43 tests (all P interaction > 0.01). Finally, we adjusted for age in addition to sex for all of the genomewide significant SNPs; with the exception of rs7942850 on chromosome 11 (P age−adjusted = 0.06), all SNPs remained nominally significant after adjustment (Supplementary Table 11) .
Expression of key genes in lung tissue
We selected 11 genes for lung tissue expression studies on the basis of localized evidence for newly discovered association with IIP (DPP9, DSP, FAM13A, IVD, DISP2 , OBFC1, ATP11A and MUC2) and/or close proximity to an association signal coupled with a priori evidence for expression differences of the gene family in IIP cases compared to controls (MUC5B, MUC2, WNT3 and WNT9B). We measured expression of these genes in lung tissue from 100 IPF cases and 94 controls using quantitative PCR and validated TaqMan Genotyping Assays (Applied Biosystems) to test for differences between cases and controls and to test for association between the genotypes at the most highly associated SNPs in each gene and expression of that gene. We confirmed our results from a smaller study 11 that MUC5B is more highly expressed in the lung tissue of cases compared to controls (P = 5.6 × 10 −11 ), but, consistent with our previous findings for rs35705950 in IPF cases, rs868903 was not associated with expression of MUC5B. DSP was more highly expressed in cases compared to controls (P = 0.0002), and expression differed by genotype at rs2076295 (P = 0.002); however, relative expression of DSP decreased with the number of copies of the putative risk allele (Fig. 4) . There are two isoforms of desmoplakin generated by alternative splicing. SNP rs2076295 is located in a binding site for transcription factor PU.1, which has been implicated in the alternative splicing of target genes 19 ; however, we saw no evidence for a differential effect of rs2076295 genotype on the expression of the primary isoform compared to the alternative isoform (data not shown). There was nominal evidence for higher expression of DPP9 in cases compared to controls (P = 0.03), but neither rs12610495 (P = 0.46) nor rs2109069 (P = 0.72) was associated with DPP9 expression. FAM13A, IVD, OBFC1 and ATP11A did not differ in expression between cases and controls or by genotype (all P > 0.12); MUC2, DISP2, WNT3 and WNT9B showed little or no expression in the lung samples.
Percent variation in disease risk explained by GWAS SNPs
We estimated the percent of disease risk explained by all 439,828 GWAS SNPs tested for association using a variance components model 20 across a range of prevalence estimates for IIP (50 per 100,000 to 100 per 100,000). We found that the GWAS SNPs could account for an estimated 28% (standard error (s.e.) of 2%) to 31% (s.e. of 3%) of the risk of IIP. Because we did not include the MUC5B promoter SNP (rs35705950) in this analysis (it was not genotyped in the 4,683 individuals in the out-of-study control population), this may be a conservative estimate of the contribution of common SNPs to risk of IIP.
DISCUSSION
These findings provide convincing evidence that common genetic variation is an important contributor to risk of IIP. We identified seven new genetic risk loci (4q22, 6p24, 7q22, 10q24, 13q34, 15q14-15 and 19p13) and confirmed the role of risk variants in three previously reported loci (TERC at 3q26, TERT at 5p15 and MUC5B at 11p15). 
A r t i c l e s
Before this report, the only common variant consistently associated with IIP was in MUC5B (rs35705950). In aggregate, the common risk variants associated with IIP suggest that this disease is primarily initiated by defects in host defense, cell-cell adhesion and DNA repair. Moreover, our findings can be used to guide intervention trials for this complex disease. Secreted mucins (MUC5B) in the distal airways seem to have a role in the development of IIP. Our data do not suggest any effects of SNPs in other genes (MUC2 or TOLLIP) in the 11p15 region after accounting for the effect of the MUC5B promoter SNP rs35705950, previously identified as a key risk factor for IIP 11 . SNP rs868903 in the promoter of the MUC5B gene was one of the most strongly associated SNPs in the GWAS, replication and meta-analysis, is not in strong LD (r 2 = 0.13) with rs35705950 and is closer to the transcription start site for MUC5B than rs35705950 (1.5 kb versus 3 kb). Although lung tissue from individuals with IIP has higher concentrations of MUC5B than controls, neither of these MUC5B promoter variants seems to be entirely responsible for the increased expression of MUC5B in individuals with IIP, suggesting that other gene variants or environmental toxins are likely to have a role in this disease. We speculate that dysregulated lung mucins initiate or exacerbate lung fibrosis through one of the following mechanisms: (i) altered mucosal defense 21 ; (ii) interference with alveolar repair 22, 23 ; or (iii) direct cell toxicity (endoplasmic reticulum stress or apoptosis 24 ), stimulating a fibroproliferative response initiated by unfolded intracellular MUC5B.
Genes that maintain the length of telomeres seem to have a role in the development of IIP. Before this report, the associations between pulmonary fibrosis and TERT and TERC involved rare variants of TERT and TERC 4,5 and potentially one common variant of TERT 10 . Mutations in these genes are associated with shortened telomeres in alveolar epithelia 25 , suggesting that these gene variants may increase the risk of pulmonary fibrosis through the disruption of intracellular homeostatic mechanisms. Moreover, dyskeratosis congenita, a congenital disorder that resembles premature aging and frequently involves pulmonary fibrosis, has been attributed to mutations in TERT and TERC 4 . Our GWAS identified common variants in TERT, near TERC and in another gene that influences telomere length, OBFC1. A common variant in OBFC1 has been associated with telomere length in two GWAS of human leukocyte telomere length in the general population 26, 27 . Whether the common variants identified here represent common risk variation or are markers of a collection of rare variants in these genes needs to be established 28, 29 . However, it seems that risk associated with these genes is not limited to rare variants. In aggregate, these findings underscore the importance of telomerase activity, telomere length and possibly early cell senescence in the pathogenesis of pulmonary fibrosis.
Our results implicate alterations in cell-cell adhesion in the risk of developing IIP. Variants in the DSP gene were strongly associated with IIP and with the expression of DSP in the lung tissue of individuals with IIP. DSP encodes desmoplakin, a component of the desmosome, an adhesive intercellular molecule that tightly links adjacent cells and forms a dynamic structure with other proteins (plakoglobin and plakophilins) that tether the cytoskeleton to the cell membrane 30 . Desmosomes are particularly important in maintaining the integrity of tissues that experience mechanical stress (such as the peripheral portions of the lung), and there is strong evidence that perturbation of the desmosome disrupts epithelial homeostasis 30 . Mutations in DSP have been associated with arrhythmogenic right ventricular dysplasia 31 , keratodermas 32, 33 and alopecia 34, 35 , directly implicating desmoplakin in diseases with loss of tissue integrity. More specifically, mutations in DSP have been associated with cardiac interstitial fibrosis on the basis of its overexpression in mouse cardiac tissue 36 . An additional potential mechanism for the involvement of DSP is through alterations in the Wnt/β-catenin signaling pathway, which have been observed in pulmonary fibrosis 37, 38 . Desmoplakin has been shown to influence the Wnt/β-catenin signaling pathway through regulation of another component of the desmosome, γ-catenin 39 . These studies provide strong biomechanical or biological rationales for genetic variation in DSP underlying pulmonary fibrosis.
Our results also implicate other cell-cell adhesion molecules in the risk of IIP development. The DPP9 gene is a member of the same protein family as fibroblast activation protein, which has been shown to be expressed in fibroblastic foci but not in adjacent healthy lung in IPF 40 . DPP9 is expressed in epithelia and has been shown to alter cell adhesion in human embryonic kidney cells 41 . In addition, the CTNNA3 gene (encoding catenin (cadherin-associated protein), α3) was nearly significant in the meta-analysis (P meta = 9.8 × 10 −7 ), is located at 10q22 and is a cell adhesion molecule that physically interacts with β-catenin 42 and mediates cell adhesion 43 . In aggregate, these findings suggest that pulmonary fibrosis may be caused by defects in cell-cell adhesion or the cytoskeleton that result in an inability to accommodate the stress associated with mechanical stretch of the lung.
FAM13A is a signal transduction gene that is responsive to hypoxia, and a SNP (rs7671167) in this gene has recently been found to be protective in chronic obstructive lung disease 44 . The ATP11A gene encodes an ATP-binding cassette (ABC) transporter 45 . Another ABC transporter (ABCA3) is expressed by type II alveolar cells, and mutations in ABCA3 have been shown to interfere with lamellar body formation and surfactant protein function and to cause surfactant protein deficiency in newborns 46 and have been associated with desquamative interstitial pneumonitis 47 and usual interstitial pneumonia 48 in children and young adults.
The other genome-wide significant loci are not as well localized to a single gene, although there are interesting candidates. At 7q22, an imputed SNP (rs6963345) is the most strongly associated SNP and is in an intron of the ZKSCAN1 gene. ZKSCAN1 is in the same family as ZKSCAN3, variation in which has been associated with airflow obstruction in a large meta-analysis of pulmonary function 49 . The DISP2 gene (encoding dispatched homolog 2) at 15q14-15 encodes a multitransmembrane protein involved in Hedgehog signaling, which is integral to embryogenesis, tissue regeneration and carcinogenesis 50 . The strongest associations at 15q14-15, however, are in or immediately upstream of the IVD gene (encoding isovalerylCoA dehydrogenase); IVD is a mitochondrial matrix enzyme involved in leucine catabolism. The association signal at 17q21 was completely confounded by local ancestry in that genomic region, marked by carriage of a common inversion polymorphism, in both the discovery and replication cohorts. As such, determining whether the haplotypes that carry the inversion contain protective variants for IIP will require investigation beyond statistical analysis, such as examination of gene expression differences between cases and controls. An obvious candidate among the genes in the region is WNT3 because alterations in Wnt signaling have been observed in IIP 37 ; however, we found no evidence of WNT3 expression in the lung.
Although it has been proposed that pulmonary fibrosis results from activation of developmental pathways 51 or aberrant lung repair 52 , our findings suggest that these mechanisms are secondary to a primary defect in host defense or cell-cell adhesion. Because we found that several genes involved in the integrity of lung epithelia (DSP, DPP9 and CTNNA3) and lung mucins (MUC5B) have IIP risk variants, we hypothesize that defects in these mechanisms primarily contribute to the development of pulmonary fibrosis. Given the importance of environmental exposures (for example, exposures to cigarette smoke, asbestos and silica) in the development of interstitial lung disease, it is logical to speculate that common inhaled particles might, over years, cause exaggerated interstitial injury in persons who have defects in lung host defense or cell-cell adhesion. Our view is that shortened telomeres and consequent changes in cell survival in combination with persistent tissue injury may primarily alter host defense or may enhance the 'host defense challenge' to the lung through endogenous mechanisms. Thus, excessive lung injury, either through greater environmental exposures, endogenous defects in critical homeostatic mechanisms or subtle defects in host defense, may, over years, lead to pulmonary fibrosis. We believe that more attention should be directed to host defense, cell-cell adhesion and telomere length when considering druggable targets for this complex disease.
Our findings should substantially influence future genetic, diagnostic and pharmacological studies of IIP. We estimated that the cumulative GWAS SNPs (excluding rs35705950) reported in this study explain approximately one-third of the variability in risk of developing IIP, suggesting that further examination of common variation in larger cohorts is warranted, in addition to studies of rare variation, epigenetic features and gene-environment interactions. Although the clinical manifestations of these diseases have been well defined 1 , it is becoming increasingly clear that each type of IIP is influenced by multiple genetic variants that likely have distinct prognoses and may respond differently to pharmacological intervention. Consequently, genotyping subjects with IIP in therapeutic trials may inform drug development by identifying agents that are effective in selected groups of patients. In fact, the lack of attention to pharmacogenetic approaches in IIP trials may explain why few agents have been found to alter the course of these diseases. Moreover, the genetic heterogeneity of IIP suggests that genetic variants may prove helpful in redefining the types of IIP and may provide more accurate prognostic information for affected individuals and their families.
URLs. Illumina, http://www.illumina.com; Sequenom, http:// www.sequenom.com; SNPGWA, https://www.phs.wfubmc.edu/ public/bios/gene/downloads.cfm; METAL, http://www.sph.umich. edu/csg/abecasis/metal/.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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for the most significantly associated SNP in that locus (at 11p15, we adjusted for rs35705950). To assess the robustness of each SNP association to age effects in addition to sex, we tested for association between IIP and each SNP adjusted for both age and sex. Finally, to test for effect modification of SNP associations by sex, we tested for association between IIP and each SNP by sex interaction.
Expression analyses. We tested for differential gene expression in the lung between 100 cases and 94 controls using a 2-sample t test. We also tested for differential expression by genotype using the combined case and control group via a test for trend across the three genotype groups unless there were <5 individuals in a genotype group; we grouped the rare homozygote and heterozygote groups together in that case. P < 0.05 was considered statistically significant.
